When treating patients with EBV encephalitis, the possibility of XLP should be considered. Once the diagnosis of XLP is made, aggressive treatment such as rituximab, and other immunosuppressive agents are desired for rapid transition to HSCT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517224 | PMC |
| http://dx.doi.org/10.1002/ccr3.7949 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A case of adult-onset X-linked lymphoproliferative disease mimicking pulmonary infection.
BMC Infect Dis
December 2024
National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
X-linked lymphoproliferative disease (XLP) is a rare primary immunodeficiency with susceptibility and vulnerability to Epstein-Barr virus (EBV) infection. Most patients were diagnosed in early childhood and do not survive into adulthood. Here we reported an adult-onset XLP patient presenting with fever, dyspnea, and pulmonary nodules, mimicking respiratory infection at disease onset.
View Article and Find Full Text PDFX-Linked Lymphoproliferative Disease Associated Hemophagocytic Lymphohistiocytosis Diagnosed Expeditiously With Ultra-Rapid Whole-Genome Sequencing.
Pediatr Blood Cancer
February 2025
Pediatric Hematology and Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Wiskott-Aldrich Syndrome: A Report of a Rare X-Linked Disorder.
Cureus
August 2024
Pediatrics, Dr. D. Y. Patil Medical College, Hospital & Research Centre, Dr. D. Y. Patil Vidyapeeth (Deemed to be University), Pune, IND.
Article Synopsis
- Wiskott-Aldrich syndrome (WAS) is a rare genetic disorder that affects mostly boys and causes issues like eczema, low platelet counts, and a weak immune system.
- A 7-month-old baby showed symptoms like slow growth, mild eczema, and frequent colds, but his platelet levels kept dropping even with treatment.
- Finally, genetic tests confirmed he had WAS, which is linked to a mutation on the X chromosome.
Lentiviral vectors for precise expression to treat X-linked lymphoproliferative disease.
Mol Ther Methods Clin Dev
December 2024
Department of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
X-linked lymphoproliferative disease (XLP1) results from gene mutations affecting the SLAM-associated protein (SAP). A regulated lentiviral vector (LV), XLP-SMART LV, designed to express SAP at therapeutic levels in T, NK, and NKT cells, is crucial for effective gene therapy. We experimentally identified 34 genomic regulatory elements of the gene and designed XLP-SMART LVs to emulate the lineage and stage-specific control of SAP.
View Article and Find Full Text PDFHaploidentical Hematopoietic Stem Cell Transplantation for Paediatric Patients with X-linked Lymphoproliferative Syndrome.
Mediterr J Hematol Infect Dis
May 2024
Department of Hematology and Oncology, Beijing Jingdu Children's Hospital, China.
The aim of this study was to investigate the prognostic factors of haploid hematopoietic stem cell transplantation in the treatment of X-linked lymphoproliferative syndrome. Seven children with X-linked lymphoproliferative syndrome diagnosed by XIAP gene analysis were enrolled. The conditioning regimens were tolerated in all seven patients, and the median time of neutrophil engraftment was 10 days (8-13 days), and that of platelet engraftment was 21 days (14-24 days).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!